A Phase 1/2 interventional study of Panobinostat and Ruxolitinib in Myelofibrosis, sponsored by John Mascarenhas. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-31.
Sponsored by John Mascarenhas · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 39th largest by enrollment, is one of 5 that started in 2013, is one of 8 in phase 1/2, and was the 14th registered.
628 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.
Browse Primary Myelofibrosis studies →8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18–75
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18–75
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 27 · Phase 3 6 · Phase 4 4
First in 2007; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 43 across 492 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 45 across the 50 interventional studies. Of the 32 that completed or were terminated, 23 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 50 have an industry lead sponsor. The 10 most frequent:
John Mascarenhas is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
11 studies in Primary Myelofibrosis by John Mascarenhas: 3 open now, 4 under way, none of them phase 3. Of 7 finished, 6 (86%) have results posted.
Among the 11 studies in Primary Myelofibrosis by John Mascarenhas, this one is the 7th largest by enrollment, is one of 2 that started in 2013, is one of 2 in phase 1/2, and was the 3rd registered.
John Mascarenhas’s Primary Myelofibrosis studies by the year they started, since 2007.
6 of the studies testing ruxolitinib in Primary Myelofibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT05714072Memorial Sloan Kettering Cancer CenterA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | 2027-01 |
| NCT06345495M.D. Anderson Cancer CenterHigh Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly | 2027-01-01 |
| NCT05371964Geron CorporationA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | 2027-02 |
| NCT03069326Memorial Sloan Kettering Cancer CenterA Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis | 2027-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, from their registry updates:
Among John Mascarenhas’s 11 in Primary Myelofibrosis:
This tab as a report to print or save as PDF → With an account.
This is a single-center, single arm, dose finding study to assess safety and tolerability of the oral combination of Panobinostat and Ruxolitinib in patients with myelofibrosis (MF) in chronic and accelerated phase.
Phase I/II open label, single institution, combination therapy trial of induction Ruxolitinib followed by combination with Panobinostat in dose escalation cohorts with a primary endpoint of determining the safety and tolerability of combination therapy in patients with myelofibrosis (MF) in chronic and accelerated phase. A 3+3standard dose escalation scheme will be employed and the occurrence of dose limiting toxicities (DLTs) will be captured and the occurrence of such events will determine dose cohort escalation by predetermined and established rules. In addition to establishing the DLTs, maximally tolerated dose (MTD), and recommended phase II dose (RPTD) in the phase I portion of this trial, exploratory biomarkers will be evaluated within phase I as well. Pharmacodynamics and exploratory genetic and epigenetic biomarkers will be explored as predictors of response to therapy. The RPTD cohort will be expanded to incorporate a total of 22 patients, including 6 from phase I, in order to assess clinical response as assessed by International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) as a primary endpoint for the phase II portion of this trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Intermediate-2 and higher by IWG-MRT Post PV/ET MF and PMF patients either in
Patients must meet the following laboratory criteria:
Exclusion Criteria:
Impaired cardiac function or cardiac diseases, including any one of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination of Panobinostat and Ruxolitinib
Drug: Panobinostat · Drug: Ruxolitinib
PO TIW QOW or PO TIW QW
Also known as: LBH589
PO BID x 28 days
Also known as: INCB424, Jakafi
Number of Patients That Achieve Stable Disease or Clinical Improvement
Number of patients that have either stable disease or clinical improvement treatment response as defined by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Stable disease (SD) - response that is not complete remission, partial remission, clinical improvement, anemia response, spleen response, symptoms response, or progressive disease. Clinical improvement (CI) - a response in anemia, splenomegaly, or MF-SB that is not associated with progressive splenomegaly or increase in severity of anemia, thrombocytopenia, or neutropenia.
Time frame: at least 6 months
Number of Participants Who Experienced Dose-Limiting (DLTs)
Panobinostat related adverse events requiring dose reduction or discontinuing prior to Cycle 6, Day 29 (C6D29)
Time frame: up to cycle 6, day 29
Percent Change in Spleen Volume
Percent change in spleen volume at C6D29 as compared to baseline
Time frame: Baseline and Cycle 6, Day 29
Percent Change in Spleen Size for Responders and Non-responders
Percent change in spleen length size by palpation at cycle 6, day 29 (C6D29) from baseline
Time frame: Cycle 6, Day 29
Percent Change in Spleen Length
Percent change in spleen length at C6D29
Time frame: Cycle 6, Day 29
Number of Participants With Percent Change on Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)
Symptom responders defined as having a percent change in MPN-SAF score from Screening/C1D1 to C6D29 of more than 50%.MPN-SAF is an 18-item instrument. Each item score 0-10 averaged, total scale from0-10, with higher score indicating more symptoms.
Time frame: baseline, C1D1 and Cycle 6 Day 29
| Milestone | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 |
|---|---|---|---|---|
| Started | 3 | 0 | 0 | 0 |
| Completed | 3 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 |
|---|---|---|---|---|
| Started | 0 | 6 | 0 | 0 |
| Completed | 0 | 6 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 |
|---|---|---|---|---|
| Started | 0 | 0 | 3 | 0 |
| Completed | 0 | 0 | 3 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 3 |
| Completed | 0 | 0 | 0 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
Number of patients that have either stable disease or clinical improvement treatment response as defined by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Stable disease (SD) - response that is not complete remission, partial remission, clinical improvement, anemia response, spleen response, symptoms response, or progressive disease. Clinical improvement (CI) - a response in anemia, splenomegaly, or MF-SB that is not associated with progressive splenomegaly or increase in severity of anemia, thrombocytopenia, or neutropenia.
| Participants | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 |
|---|---|---|---|---|
| Stable disease | 3 | 4 | 1 | 3 |
| Clinical Improvement | 0 | 1 | 2 | 0 |
| No response evaluated | 0 | 1 | 0 | 0 |
Panobinostat related adverse events requiring dose reduction or discontinuing prior to Cycle 6, Day 29 (C6D29)
| Participants | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 |
|---|---|---|---|---|
| requiring Panaobinostat dose reduction | 1 | 0 | 3 | 1 |
| Discontinuing Panobinostat | 0 | 2 | 0 | 0 |
Percent change in spleen volume at C6D29 as compared to baseline
| percent change | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 |
|---|---|---|---|---|
| Percent Change in Spleen Volume | -41 (-44 to -8) | -8 (-61 to 25) | -40 (-59 to 4) | -17 (-29 to -15) |
Percent change in spleen length size by palpation at cycle 6, day 29 (C6D29) from baseline
| percent change | Responders | Non-Responders |
|---|---|---|
| Percent Change in Spleen Size for Responders and Non-responders | -100 (-100 to -14) | -29 (-100 to 0) |
Percent change in spleen length at C6D29
| percent change | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 |
|---|---|---|---|---|
| Percent Change in Spleen Length | -83 (-100 to -29) | -17 (-100 to 0) | -14 (-100 to 0) | -31 (-33 to -29) |
Symptom responders defined as having a percent change in MPN-SAF score from Screening/C1D1 to C6D29 of more than 50%.MPN-SAF is an 18-item instrument. Each item score 0-10 averaged, total scale from0-10, with higher score indicating more symptoms.
| Participants | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 |
|---|---|---|---|---|
| Number of Participants With Percent Change on Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) | 1 | 2 | 0 | 0 |
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panobinostat and Ruxolitinib Cohort 1 | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Panobinostat and Ruxolitinib Cohort 2 | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Panobinostat and Ruxolitinib Cohort 3 | 0/3 (0%) | 3/3 (100%) | 3/3 (100%) |
| Panobinostat and Ruxolitinib Cohort 4 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Event | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 |
|---|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 1/3 | 2/6 | 2/3 | 0/3 |
| FatigueGeneral disorders | 0/3 | 0/6 | 1/3 | 0/3 |
| Night SweatsGeneral disorders | 0/3 | 0/6 | 1/3 | 0/3 |
| HypertensionVascular disorders | 1/3 | 2/6 | 0/3 | 0/3 |
| VomitingGastrointestinal disorders | 1/3 | 0/6 | 0/3 | 0/3 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 0/3 | 0/6 | 1/3 | 0/3 |
| Upper Respiratory InfectionRespiratory, thoracic and mediastinal disorders | 1/3 | 0/6 | 0/3 | 0/3 |
| Squamous Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 2/6 | 0/3 | 0/3 |
| Atrial fibrillationCardiac disorders | 0/3 | 0/6 | 1/3 | 0/3 |
| FeverGeneral disorders | 0/3 | 0/6 | 1/3 | 0/3 |
| Event | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 |
|---|---|---|---|---|
| DiarrheaGastrointestinal disorders | 3/3 | 3/6 | 2/3 | 2/3 |
| DysphagiaNervous system disorders | 0/3 | 0/6 | 3/3 | 0/3 |
| AnemiaBlood and lymphatic system disorders | 1/3 | 2/6 | 2/3 | 2/3 |
| Upper Respiratory InfectionInfections and infestations | 1/3 | 4/6 | 2/3 | 1/3 |
| HeadacheNervous system disorders | 1/3 | 2/6 | 0/3 | 2/3 |
| Abdominal painGastrointestinal disorders | 2/3 | 1/6 | 1/3 | 0/3 |
| FlatulenceGastrointestinal disorders | 1/3 | 0/6 | 1/3 | 2/3 |
| Back PainMusculoskeletal and connective tissue disorders | 1/3 | 1/6 | 2/3 | 0/3 |
| DysuriaRenal and urinary disorders | 2/3 | 0/6 | 0/3 | 0/3 |
| Gastroesophageal RefluxGastrointestinal disorders | 2/3 | 0/6 | 0/3 | 0/3 |
| Age, Continuous(years) | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 | Total |
|---|---|---|---|---|---|
| Median | 60 (53 to 74) | 61 (52 to 78) | 69 (46 to 78) | 64 (64 to 66) | 64 (46 to 78) |
| Sex: Female, Male(Participants) | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 | Total |
|---|---|---|---|---|---|
| Female | 1 | 1 | 1 | 1 | 4 |
| Male | 2 | 5 | 2 | 2 | 11 |
| Race and Ethnicity Not Collected(Participants) | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 | Total |
|---|---|---|---|---|---|
| Count of participants | — | — | — | — | 0 |
| Disease subtype(Participants) | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 | Total |
|---|---|---|---|---|---|
| Primary myelofibrosis (PMF) | 1 | 3 | 1 | 1 | 6 |
| Post essential thrombocythemia PET-MF | 2 | 3 | 1 | 1 | 7 |
| Post polycythemia vera PPV-MF | 0 | 0 | 1 | 1 | 2 |
| DIPSS Score(Participants) | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 | Total |
|---|---|---|---|---|---|
| low (score 0) | 1 | 0 | 0 | 0 | 1 |
| intermediate-1 (score 1 or 2) | 0 | 2 | 3 | 1 | 6 |
| intermediate-2 (score 3 or 4) | 2 | 4 | 0 | 2 | 8 |
| JAK2^V617F positive(Participants) | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 | Total |
|---|---|---|---|---|---|
| Count of participants | 3 | 4 | 2 | 1 | 10 |
| Cytogenetics(Participants) | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 | Total |
|---|---|---|---|---|---|
| Unfavorable Karyotype | 0 | 2 | 0 | 0 | 2 |
| Not Unfavorable Karyotype | 1 | 4 | 3 | 3 | 11 |
| Not available | 2 | 0 | 0 | 0 | 2 |
| Prior Myelofibrous (MF) Directed Therapy(Participants) | Panobinostat and Ruxolitinib Cohort 1 | Panobinostat and Ruxolitinib Cohort 2 | Panobinostat and Ruxolitinib Cohort 3 | Panobinostat and Ruxolitinib Cohort 4 | Total |
|---|---|---|---|---|---|
| Count of participants | 2 | 6 | 2 | 1 | 11 |
9 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Jan 2013, a primary completion of May 2018 and a completion of May 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2023, 5 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Panobinostat · Ruxolitinib
John Mascarenhas